Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CCR9 | P51686 | 6/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650351 | 0.85 | TRPV4 (0.51) | SLC22A12MCL1 | |
| SCHEMBL16325840 | 0.83 | SLC22A12 (0.47) | SLC22A12HSD11B1ACLYPIK3C3L3MBTL1 | |
| SCHEMBL13852847 | 0.83 | ACLY (0.53) | HSD11B1CCR9MCL1ACLYHSD17B2 | |
| SCHEMBL27761878 | 0.81 | SLC22A12 (0.58) | SLC22A12MCL1ACLYL3MBTL1 | |
| SCHEMBL13852834 | 0.81 | MCL1 (0.59) | MCL1ACLYHSD17B2 | |
| SCHEMBL13615340 | 0.81 | MCL1 (0.60) | MCL1ACLYL3MBTL1 | |
| SCHEMBL13852823 | 0.79 | MCL1 (0.59) | HSD11B1MCL1ACLYHSD17B2L3MBTL1 | |
| SCHEMBL13615230 | 0.77 | SLC22A12 (0.48) | SLC22A12HSD11B1PIK3C3 | |
| SCHEMBL13615244 | 0.76 | NHERF1 (0.65) | HSD11B1MCL1ACLYHSD17B2L3MBTL1 | |
| SCHEMBL4898138 | 0.75 | SLC22A12 (0.57) | SLC22A12HSD11B1CCR9MCL1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | SLC22A12 4663/4885HSD11B1 4693/4885CCR9 3942/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | SLC22A12 4627/4885HSD11B1 4710/4885CCR9 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.